Researchers have published a systematic web search cataloguing clinics that use direct-to-consumer advertising to sell off-label ketamine across the New York metropolitan area, one of the densest healthcare markets in the country. The study, from a team including NYU’s Joseph Palamar, a drug-epidemiology researcher who also serves as deputy director of the federally funded National Drug Early Warning System, applies to a major metro area a methodology that, when run elsewhere, turned up extensive misrepresentation of ketamine’s approval status, risks, and evidence base. The value of this kind of study is not the individual finding. It is the baseline: for oversight to work, someone first has to count what is actually being advertised and check it against the facts.
Why an ad-mapping study is the right instrument
Ketamine’s off-label market has grown quickly and with little coordinated oversight. Intravenous ketamine is FDA-approved only as an anesthetic; every psychiatric use, delivered in a clinic or via telehealth, is off-label. Esketamine, the related but distinct nasal spray, is FDA-approved for treatment-resistant depression, but only under a Risk Evaluation and Mitigation Strategy that requires in-clinic administration and two hours of monitored observation. Between those two facts sits a large, loosely regulated space: clinics advertising ketamine infusions, sublingual lozenges, and take-home prescriptions for depression, anxiety, PTSD, and pain, direct to consumers, often via telehealth intake with no in-person visit required. A systematic web search, identifying every advertiser in a region and coding what each one claims, is how researchers turn that sprawl into countable data.
What the comparable study found
A methodologically similar study, run in Maryland by researchers at the University of Colorado and Johns Hopkins, is the clearest available preview of what this kind of mapping tends to surface. It identified 17 advertisers operating across 26 locations in a single state, charging $360 to $2,500 per infusion, promoting the drug for depression, PTSD, anxiety, chronic pain, and beyond. The advertising problems were specific and countable: seven of the seventeen advertisers failed to disclose ketamine’s potential for adverse effects, three explicitly and falsely claimed the drug is not addictive, ten did not disclose that the psychiatric use being advertised was off-label, and one falsely claimed FDA approval for treating depression outright. The researchers behind that study also estimated, from compiling national clinic directories, that roughly 800 such clinics operate across the country. If the discrepancy in that region held, it would not have been a few bad actors. It would have been close to half the market misrepresenting the drug in some material way.
Why New York raises the stakes
None of those Maryland-specific figures should be assumed to transfer directly to New York; the new study has its own count and its own findings, which this piece is not asserting. What can be said is that the New York metro area is a fundamentally larger and denser market than the one previously studied, which means the study is more likely to surface a large, quantifiable pattern than a handful of outliers, and any oversight gaps it documents affect a correspondingly larger patient population. Applying a validated methodology to a bigger, more consequential market is exactly the right next step for building the kind of empirical baseline that regulators and platforms eventually have to act on.
Where this study sits in the broader picture
The desk has tracked ketamine’s expansion into new indications alongside the countervailing safety literature, misuse patterns without standardized measurement criteria, and cumulative-exposure hepatotoxicity risk that mostly shows up above psychiatric dosing. Advertising oversight is the third leg of that safety stool, sitting upstream of both: before a patient is ever dosed, what were they told the drug was, how well-established was it claimed to be, and were the risks disclosed at all. A pattern of misleading advertising compounds the other risks, because patients making an expensive, out-of-pocket, high-stakes decision are doing so on the basis of claims that, in the one comparable region studied, were frequently inaccurate.
The caveats
This piece deliberately does not report the New York-specific findings, because they were not available to confirm independently at time of writing; it reports the study’s existence, its credible authorship, and its methodology, and uses the Maryland study strictly as an illustrative precedent, clearly labeled as such. The Maryland numbers describe Maryland, not New York, and a larger, wealthier, more saturated market could look better or worse. Advertising violations are not the same as clinical harm; a clinic misrepresenting FDA status is a real problem, but it does not by itself mean patients are being harmed, only that they are being poorly informed. And systematic web searches capture what is publicly advertised, not what happens in the clinical encounter itself, which is a narrower and different kind of oversight gap than clinical-quality monitoring would address.
The frame
The regulatory conversation around off-label ketamine has mostly proceeded on anecdote, a viral horror story, an FDA warning letter, a lawsuit. What actually enables systematic oversight is unglamorous: someone has to count the clinics, log their claims, and check those claims against the facts. That is what this kind of study does, and doing it in one of the country’s largest healthcare markets raises the number of patients any resulting oversight action would actually reach. The prior baseline elsewhere found a market where misrepresentation was common rather than rare. Whether New York looks similar is now a documented, checkable question rather than a guess, and that is the useful thing this study provides regardless of which way its own numbers land.